Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reply to Correspondence

Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”

Eileen Laurel Yoon, Dae Won Jun

Clin Mol Hepatol. 2024;30(4):1033-1034. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0360

View: 853 Download: 23

Letter to the Editor

Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2024;30(4):982-986. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0691

View: 760 Download: 47

Differences in major adverse cardiovascular events of metabolic dysfunction-associated steatotic liver disease by race and ethnicity: Letter to the editor on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Hui-Chin Chang, Wen-Chieh Liao, Yi-Jen Fang, Shiu-Jau Chen, Shuo-Yan Gau

Clin Mol Hepatol. 2024;30(4):978-981. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0565

View: 705 Download: 46

Original Article

Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan

Chung-Feng Huang, Chia-Yen Dai, Yi-Hung Lin, Chih-Wen Wang, Tyng-Yuan Jang, Po-Cheng Liang, Tzu-Chun Lin, Pei-Chien Tsai, Yu-Ju Wei, Ming-Lun Yeh, Ming-Yen Hsieh, Chao-Kuan Huang, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(4):883-894. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0414

View: 1021 Download: 88

DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease

Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim, on behalf of the Innovative Target Exploration of NAFLD (ITEN) Consortium

Clin Mol Hepatol. 2024;30(4):824-844. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0229

View: 1586 Download: 258

Correspondence

Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”

Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):287-290. Published online February 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0136

View: 2244 Download: 71 Crossref: 1

Original Article

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression

Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):247-262. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0449

View: 3966 Download: 262 Web of Science: 6 Crossref: 7

Editorial

The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective

Carlos Jose Pirola, Silvia Sookoian

Clin Mol Hepatol. 2024;30(2):174-176. Published online February 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0082

View: 2506 Download: 75 Web of Science: 1 Crossref: 1

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2024;30(2):168-170. Published online March 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0140

View: 2585 Download: 82 Web of Science: 3 Crossref: 2

Adding to the confusion in more than just the name

Jacob George

Clin Mol Hepatol. 2023;29(4):973-976. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0367

View: 2191 Download: 76 Web of Science: 6 Crossref: 6

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials

Ming-Lun Yeh, Ming-Lung Yu

Clin Mol Hepatol. 2023;29(4):969-972. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0359

View: 2831 Download: 174 Web of Science: 8 Crossref: 8

Review

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Received April 10, 2024 Accepted June 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0246 [Accepted]

View: 2626 Download: 144 Crossref: 1

Precision medicine and nucleotide-based therapeutics to treat MASH

Andrea Caddeo, Stefano Romeo

Received June 8, 2024 Accepted August 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0438 [Accepted]

View: 1259 Download: 247 Crossref: 2

Correspondence

PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD

Baokai Sun, Likun Zhuang

Received September 3, 2024 Accepted September 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0744 [Accepted]

View: 366 Download: 55

Correspondence on Letter regarding “A complement to epigenetics in MASLD”

Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim

Received September 6, 2024 Accepted September 9, 2024

DOI: https://doi.org/10.3350/cmh.2024.0761 [Accepted]

View: 324 Download: 27

Original Article

USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination

Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li

Received June 25, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0478 [Accepted]

View: 1159 Download: 322

Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments

Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian

Received May 15, 2024 Accepted October 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0359 [Accepted]

View: 574 Download: 83

Bariatric Surgery Reduces Long-Term Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Cirrhosis

Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen

Received July 15, 2024 Accepted November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0564 [Accepted]

View: 531 Download: 29

Review Article

Mechanisms of HCC and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Received September 25, 2024 Accepted November 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837 [Accepted]

View: 285 Download: 39

Review

Microbiome-Centered Therapies for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Received September 13, 2024 Accepted November 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811 [Accepted]

View: 332 Download: 39

Original Article

Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Received November 3, 2024 Accepted November 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0987 [Accepted]

View: 139 Download: 15

1 |

Viewed By 5041	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 4909	MAFLD: How is it different from NAFLD?
Viewed By 4421	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4338	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4291	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 197	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 137	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search